Breaking News Instant updates and real-time market news.

OPNT

Opiant Pharmaceuticals

$26.79

-10.19 (-27.56%)

, SHPG

Shire

$157.83

-1.87 (-1.17%)

09:20
09/15/17
09/15
09:20
09/15/17
09:20

On The Fly: Pre-market Movers

HIGHER: Opiant Pharmaceuticals (OPNT), up 3.8% after saying Narcan Nasal Spray surpassed $25M of net sales in the first half of 2017... Shire (SHPG), up 1.8% after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended extensions of indications for Shire's Firazyr... LightPath (LPTH), up 17.4% after reporting quarterly results. DOWN AFTER EARNINGS: Oracle (ORCL), down 4.5%... TEN Ltd. (TNP), down 2.2%. ALSO LOWER: Nucor (NUE), down 2.7% after lowering its third quarter EPS guidance... Cummins (CMI), down 1.5% after its 1.786M share Block Trade priced at $165.45... T2 Biosystems (TTOO), down 31.1% after its 4.38M share Spot Secondary priced at $4.00.

OPNT

Opiant Pharmaceuticals

$26.79

-10.19 (-27.56%)

SHPG

Shire

$157.83

-1.87 (-1.17%)

LPTH

LightPath

$2.41

-0.17 (-6.59%)

ORCL

Oracle

TNP

TEN, Ltd.

NUE

Nucor

CMI

Cummins

TTOO

T2 Biosystems

$6.08

-0.7 (-10.32%)

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 30

    Nov

  • 15

    Sep

  • 15

    Sep

OPNT Opiant Pharmaceuticals
$26.79

-10.19 (-27.56%)

SHPG Shire
$157.83

-1.87 (-1.17%)

08/22/17
JEFF
08/22/17
NO CHANGE
JEFF
Buy
Shire CFO departure timing 'inopportune,' says Jefferies
Jefferies analyst David Steinberg called the "surprising move" of Shire CFO Jeff Poulton out of his current post and into a role at an agriculture biotech start-up "naturally raises some concerns" given the recent departure of the company's head of R&D, adding that the timing is "highly inopportune." However, after speaking with Poulton, the analyst's take is that the move is motivated by an interest in a more entrepreneurial opportunity. Steinberg keeps a Buy rating on Shire shares, which slid 3% yesterday.
07/14/17
CANT
07/14/17
NO CHANGE
CANT
Worries about Shire hemophilia franchise overdone, says Cantor
After speaking with a pediatric hematology/oncology physician, Cantor analyst Louise Chen reports that the doctor said that uptake of Roche's (RHHBY) hemophilia treatment, ACE910, "will be gradual" because of safety concerns. The analyst says that worries about Shire's (SHPG_) hemophilia franchise are overdone. She keeps a $222 price target and an Overweight rating on the stock.
07/11/17
COWN
07/11/17
NO CHANGE
Target $325
COWN
Outperform
Shire hemophilia franchise being valued near zero, says Cowen
Cowen analyst Ken Cacciatore believes Shire's (SHPG) current valuation reflects essentially no value for the company's hemophilia franchise. Investors are treating Shire/Baxalta's hemophilia franchise as if it should equate to essentially zero, into perpetuity, beginning in 2020, Cacciatore tells investors in a research note, citing his analysis. He believes this sentiment, based on competitive concerns from Roche (RHHBY) and Alnylam (ALNY), is a "gross overreaction." The analyst has an Outperform rating on Shire with a $325 price target.
08/16/17
EVER
08/16/17
INITIATION
Target $196
EVER
Outperform
Shire initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Shire with an Outperform and a $196 price target.
LPTH LightPath
$2.41

-0.17 (-6.59%)

01/10/17
DOTC
01/10/17
INITIATION
Target $2.5
DOTC
Buy
LightPath initiated with a Buy at Dougherty
Dougherty analyst Joe Maxa initiated LightPath with a Buy and a $2.50 price target.
12/22/16
ROTH
12/22/16
INITIATION
Target $2.5
ROTH
Buy
LightPath initiated with a Buy at Roth Capital
Roth Capital analyst Matt Koranda started LightPath with a Buy rating and $2.50 price target saying the business has reached a positive organic inflection point, generating attractive profitability driven by double digit end market growth and strong product cost performance.
ORCL Oracle

09/15/17
ADAM
09/15/17
NO CHANGE
Target $57
ADAM
Buy
Oracle key metrics better than expected, says Canaccord
Canaccord analyst Richard Davis said Oracle posted its third consecutive positive quarterly surprise, with most of the key metrics at least a little better than expected. He said his view remains unchanged and that the stock will outperform in down or choppy markets. Davis reiterated his Buy rating and raised his price target to $57 from $56 on Oracle shares.
09/15/17
UBSW
09/15/17
NO CHANGE
Target $57
UBSW
Buy
Oracle price target raised to $57 from $52 at UBS
UBS analyst Fatima Boolani raised her price target on Oracle to $57 from $52 following good Q1 results in what is normally a slow quarter. The analyst noted Q2 has tougher comps, causing the guidance to be somewhat mixed. Boolani reiterated her Buy rating on Oracle shares.
09/15/17
JMPS
09/15/17
NO CHANGE
JMPS
Market Perform
JMP says Oracle Q2 guidance suggests prior cloud assumptions too optimistic
JMP Securities analyst Patrick Walravens said Oracle reported "solid" Q1 results, but he blames the afterhours slide in the stock to high expectations coming into the call and constant currency guidance that missed estimates. The analyst, who said the Q2 guidance suggests that his prior cloud growth assumptions were too optimistic, keeps a Market Perform rating on Oracle shares, which are down over 4% to $50.55 in pre-market trading.
TNP TEN, Ltd.

12/20/16
MAXM
12/20/16
INITIATION
Target $9
MAXM
Buy
Tsakos Energy initiated with a Buy at Maxim
Maxim initiated Tsakos Energy with a Buy and a $9 price target.
01/13/17
FBCO
01/13/17
DOWNGRADE
Target $5
FBCO
Neutral
Tsakos Energy downgraded to Neutral from Outperform at Credit Suisse
08/02/17
WELS
08/02/17
DOWNGRADE
Target $3.25
WELS
Market Perform
TEN Ltd. downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded TEN Ltd to Market Perform from Outperform and reduced its price target to $3.25 from $5. Analyst Michael Webber said demand headwinds from OPEC, US production, ect, and Q2 newbuild orders will likely push an industry sustained day rate recovery into 2019.
NUE Nucor

09/14/17
SBSH
09/14/17
UPGRADE
Target $65
SBSH
Buy
Nucor upgraded to Buy from Neutral at Citi
Citi analyst Alexander Hacking upgraded Nucor to Buy saying the share performance, down 10% year-to-date, is disconnected from the company's underlying fundamentals. The valuation is now attractive while steel prices in key products appear well supported, Hacking tells investors in a research note. He keeps a $65 price target for the shares.
09/12/17
09/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Neutral from Long-Term Buy at Hilliard Lyons with analyst Kurt Kemper citing share appreciation as shares have approached his previous $65 price target. 2. Bunge (BG) downgraded to Hold from Buy at Vertical Group citing the acquisition of 70% interest in IOI Loders Croklaan. 3. Advance Auto Parts (AAP) downgraded to Sell from Neutral at Citi with analyst Kate McShane saying the company's turnaround seems to be taking longer given the number of issues to fix, and its cost savings are unlikely to impact earnings given its needed investments. 4. Precision Drilling (PDS) downgraded to Neutral from Overweight at JPMorgan. 5. Nucor (NUE) and Steel Dynamics (STLD) were downgraded to Equal Weight from Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
09/12/17
DOWNGRADE

Equal Weight
Nucor, Steel Dynamics downgraded on margin concerns at Morgan Stanley
As previously reported, Morgan Stanley analyst Piyush Sood downgraded Nucor (NUE) and Steel Dynamics (STLD), each to Equal Weight from Overweight, contending that the crosscurrents of higher U.S. steel and scrap pricing and weaker non-residential and auto demand are a drag on these "mini mills" and peer Commercial Metals (CMC). However, the net impact of the pricing and demand factors is beneficial to U.S. Steel (X), added Sood, who keeps an Overweight rating on that stock.
09/12/17
MSCO
09/12/17
DOWNGRADE
MSCO
Equal Weight
Nucor downgraded to Equal Weight from Overweight at Morgan Stanley
CMI Cummins

08/07/17
GSCO
08/07/17
NO CHANGE
GSCO
Deere added to Conviction Buy List, Cummins removed at Goldman Sachs
Goldman analyst Jerry Revich added Deere (DE) to the Conviction Buy List and removed Cummins (CMI) saying he sees greater cyclical upside for farm equipment compared to global truck, resulting in higher relative earnings and revenue upside for Deere. Both stocks remain Buy rated.
09/05/17
BUCK
09/05/17
INITIATION
BUCK
Buy
Cummins initiated with a Buy at Buckingham
Buckingham analyst Neil Frohnapple started coverage of Cummins with a $180 price target and a Buy rating. The analyst sees the stock as "an attractive avenue to play increasing North American commercial vehicle builds over the next few years and a recovery in global off-highway markets." He thinks that the stock's risk/reward ratio is positive.
08/07/17
GSCO
08/07/17
DOWNGRADE
GSCO
Buy
Cummins downgraded to Buy from Conviction Buy at Goldman Sachs
08/07/17
08/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he underappreciated generic pricing pressure risks on Teva's dividend and expects declining earnings power, combined with high leverage equal to result in a longer recovery. 2. Cummins (CMI) downgraded to Buy from Conviction Buy at Goldman Sachs. 3. RE/MAX Holdings (RMAX) downgraded to Equal Weight from Overweight at Stephens. 4. Intrepid Potash (IPI) downgraded to Sell from Neutral at UBS with analyst John Roberts saying that while bankruptcy risk has been "significantly reduced" since the share count was increased 60% with the March secondary, he remains concerned about the lack of long term growth in non-core income and "still depressed" core potash related income. Roberts cites valuation for his downgrade and raised his price target for Intrepid Potash shares to $2.50 from $2.00. 5. Eaton (ETN) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TTOO T2 Biosystems
$6.08

-0.7 (-10.32%)

11/10/16
LEER
11/10/16
INITIATION
Target $5
LEER
Market Perform
T2 Biosystems resumed with a Market Perform at Leerink
Leerink analyst Puneet Souda resumed coverage of T2 Biosystems with a Market Perform rating and $5 price target.
09/11/17
09/11/17
NO CHANGE

T2 Biosystems submits 510(k) application to FDA for review of T2Bacteria panel
T2 Biosystems announced that it has filed a 510(k) premarket submission for the T2Bacteria Panel with the FDA. The T2Bacteria Panel is designed to run on the FDA-cleared T2Dx Instrument. The T2Bacteria Panel, once FDA cleared, combined with the commercially available T2Candida Panel is designed to be the first comprehensive rapid diagnostic solution on the market that identifies pathogens associated with sepsis within hours instead of days, potentially enabling 95% of patients with bloodstream infections to receive targeted therapy within 8 hours of blood draw.
03/14/17
MSCO
03/14/17
DOWNGRADE
Target $5
MSCO
Underweight
T2 Biosystems downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Steve Beuchaw downgraded T2 Biosystems to Underweight and lowered his price target for the shares to $5 from $6. The company last week disclosed that its CFO Shawn Lynch resigned effective immediately. Lynch indicated that he resigned for personal reasons and that his resignation was not the result of any disagreement with the management or the board, T2 added. The stock closed the trading day unchanged at $6.07.
05/08/17
BTIG
05/08/17
UPGRADE
Target $4
BTIG
Neutral
T2 Biosystems upgraded to Neutral from Sell at BTIG
BTIG analyst Karen Koski upgraded T2 Biosystems to Neutral saying shares have fallen below her prior $4 price target and believes the upcoming panel for T2Bacteria will act as a positive catalyst.

TODAY'S FREE FLY STORIES

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary  »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

ITEK

Inotek Pharmaceuticals

17:04
01/19/18
01/19
17:04
01/19/18
17:04
Hot Stocks
Boxer Capital reports 5.3% passive stake in Rocket Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$32.80

0.35 (1.08%)

17:03
01/19/18
01/19
17:03
01/19/18
17:03
Syndicate
Breaking Syndicate news story on Oil States »

Oil States files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

, QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

16:43
01/19/18
01/19
16:43
01/19/18
16:43
Hot Stocks
Broadcom receives second request from FTC for proposed Qualcomm deal »

Broadcom (AVGO) announced…

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRNC

tronc

$19.53

0.3 (1.56%)

16:37
01/19/18
01/19
16:37
01/19/18
16:37
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, WSJ says »

Ross Levinsohn, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AP

Ampco-Pittsburgh

$14.20

0.15 (1.07%)

16:35
01/19/18
01/19
16:35
01/19/18
16:35
Syndicate
Breaking Syndicate news story on Ampco-Pittsburgh »

Ampco-Pittsburgh files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

, UBSH

Union Bankshares

$38.79

0.54 (1.41%)

16:33
01/19/18
01/19
16:33
01/19/18
16:33
Hot Stocks
Carlyle Group reports 6% passive stake in Union Bankshares »

In a regulatory filing,…

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

UBSH

Union Bankshares

$38.79

0.54 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ANDX

Andeavor Logistics

$52.52

0.12 (0.23%)

16:31
01/19/18
01/19
16:31
01/19/18
16:31
Hot Stocks
Andeavor Logistics raises quarterly cash distribution to $1.00 per unit »

The fourth quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

16:30
01/19/18
01/19
16:30
01/19/18
16:30
Options
Preliminary option volume of 22.8M today »

Preliminary option volume…

TRNC

tronc

$19.53

0.3 (1.56%)

16:26
01/19/18
01/19
16:26
01/19/18
16:26
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, DJ says »

Dow Jones added that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RKDA

Arcadia Biosciences

$0.27

0.0285 (11.88%)

16:25
01/19/18
01/19
16:25
01/19/18
16:25
Conference/Events
Arcadia Biosciences to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.